European Network for Optimization of Veterinary Antimicrobial Therapy (ENOVAT) Guidelines for Antimicrobial Use in Canine Acute Diarrhoea.
Antibiotics
GRADE
antimicrobial stewardship
enteritis
evidence based
Journal
Veterinary journal (London, England : 1997)
ISSN: 1532-2971
Titre abrégé: Vet J
Pays: England
ID NLM: 9706281
Informations de publication
Date de publication:
27 Jul 2024
27 Jul 2024
Historique:
received:
03
06
2024
revised:
18
07
2024
accepted:
23
07
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
29
7
2024
Statut:
aheadofprint
Résumé
Acute diarrhoea is a common presentation in dogs, and a common reason for antimicrobial prescription and nutraceutical use. This evidence-based guideline provides recommendations for antimicrobial and probiotic treatment of canine acute diarrhoea (CAD). A multidisciplinary panel developed the recommendations by adhering to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. The opinions of stakeholders (general veterinary practitioners and dog owners) were collected and incorporated to ensure the applicability of this guideline. Four strong recommendations informed by high certainty evidence, and three conditional recommendations informed by very low or low certainty evidence, were drafted by the panel, along with an ungraded section on diagnostic work-up of dogs with acute diarrhoea. The ENOVAT guidelines initiative encourages national or regional guideline makers to use the evidence presented in this document, and the supporting systematic review, to draft national or local guidance documents.
Identifiants
pubmed: 39074542
pii: S1090-0233(24)00147-3
doi: 10.1016/j.tvjl.2024.106208
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106208Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement This article is based upon work from the COST Action European Network for Optimization of Veterinary Antimicrobial Treatment (CA18217), supported by COST (European Cooperation in Science and Technology). The panel members did not have any substantial conflicts of interest at the time of drafting recommendations. However, it should be noted that most of the panel members are involved in antimicrobial stewardship activities. Two panel members (MW and SU) were authors of trials included in the systematic reviews and did not participate in the risk of bias assessment or any other individual quality assessments for these publications.